TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06020131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Mobility Rehabilitation
Description: Thoracic mobility exercises: Thoracic extension on foam roller, Sidelying thoracic rotation, Quadruped thoracic rotation, Squat with extension and rotation ( 10 reps x 3 set - 2 times x wk - 8 wk)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbopelvic Stability Rehabilitation
Description: Lumbopelvic Stabilization Exercises : Bridge with alternate leg, Single leg bridge, Four point kneeling with arm and leg extension, Side plank on front arm with knee flexed (right, left), Sitting on a Swiss Ball and hip flexion (10 reps x 3 set - 2times/wk - 8 wk)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ankle Strengthening Home Exercises
Description: Ankle Strengthening exercises with resistive band (dorsiflexion, plantarflexion, inversion, eversion) (10 reps x 3 set - 3 times/wk)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ankle Strengthening Home Exercises
Description: Ankle Strengthening exercises with resistive band (dorsiflexion, plantarflexion, inversion, eversion) (10 reps x 3 set - 3 times/wk)
Study: NCT04630912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: There is no specific protocol for ACT with dementia, therefore a published ACT protocol, 'Better Living with Illness' (Brassington et al., 2016), will be used flexibly to guide the intervention.
Study: NCT05831735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The 6-month APA program is supervised via the videoconference platform and/or carried out independently based on a personalized written program that is updated weekly. The program is based on structured sessions alternating 3 types of PA: aerobic sessions, stretching sessions and muscle strengthening sessions (to be practiced following the teacher's oral or written instructions).~The sessions last from 20 minutes to 1 hour and are of low to moderate intensity depending on the initial level of fitness. The sessions are structured, adapted and progressive. During the sessions, the exercises are adapted according to the means and materials available to the patients at home or in their immediate environment.~The patients will be progressively led to practice in an autonomous way (i.e., without supervision) but following an adapted, personalized and structured program. These PA sessions can be declared afterwards to the PA teacher,(duration and the exercises actually performed).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity and education
Description: In addition to the intervention in physical activity, the people participating in this program will benefit from 6 months of educational activity (EA). The EA program includes 6 sessions scheduled according to the patients' availability in groups and by videoconference.~Following their entry into the study and their allocation to the programs (1 month maximum), the patients will be invited to a first individual EA session, in order to establish an educational diagnosis (1 hour). This session will allow for an assessment of their needs and the presentation of the workshops. Then, between the second and the sixth month following randomization, patients will benefit from 5 collective EA sessions per group of 6 patients maximum (1h30 to 2h). These sessions will be about PA, nutrition, pain management. An individual session will be held at the end of the intervention and will allow for an educational assessment.
Study: NCT04829760

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: Participants will consume 10 grams of fiber from psyllium in two doses each day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coarse wheat bran
Description: Participants will consume 10 grams of fiber from coarse wheat bran in two doses each day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Participants will consume maltodextrin in a volume equivalent to the psyllium intervention (\~2 tablespoons) in two doses each day for 8 weeks
Study: NCT05927779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFX06 tablet
Description: TFX06 tablet taken orally
Study: NCT04783116

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant stanols (3g/day)
Description: Oral consumption of 6 plant stanol enriched chews per day for 6 months (total dosage is 3g/day). Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral consumption of 6 placebo chews per day for 6 months. Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
Study: NCT06031220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep breathing exercise inform of diaphragmatic and costal breathing
Description: deep breathing exercise inform of diaphragmatic and costal breathing 3times a day for 15 repetitions each exercise for 9 weeks,
Study: NCT05811221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine of single injection
Description: Single group: give esketamine 0.75 mg/kg at the time of induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine of Intermittent injection
Description: Intermittent group: give esketamine 0.5mg/kg during anesthesia induction, and during the measuring ring esketamine 0.25mg/kg was given again
Study: NCT05840471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose water 5%
Description: This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
Study: NCT04387071

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLP-encapsulated TLR9 Agonist CMP-001
Description: Given SC and IT
Study: NCT05146726

Intervention type: OTHER
Intervention: BARMER anemia treatment
Description: BARMER insured patients are informed about the machine autotransfusion directly by the patient blood management (PBM) service and its intraoperative use is organized. The aim of these measures is to ensure that the intraoperative transfusion trigger does not fall below the intraoperative transfusion trigger by integrating the PBM into standard care and to avoid a perioperative transfusion. In addition, a postoperative treatment recommendation is made for the cause-related anemia treatment, e.g. in order to reduce the risk of a renewed anemia-related perioperative transfusion risk in the event of a possible follow-up operation or other elective operations.

Intervention type: OTHER
Intervention: NON-BARMER anemia treatment
Description: Patients not insured with BARMER also receive early anemia detection, selection according to indication intervention (transfusion probability\> 10%) and evaluation for machine autotransfusion through the above-mentioned patient blood management (PBM) restructuring of standard care. In the case of preoperative anemia before an indication intervention and / or an intervention with machine autotransfusion application, the operating clinic will be given a recommendation by the PBM service for the diagnosis and treatment of the preoperative anemia and / or the use of the machine autotransfusion (implementation is the responsibility of the operating clinic)
Study: NCT05309720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glyaderm
Description: All included patients will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. Next, the dermal substitute Glyaderm followed by a split thickness skin graft will be transplanted on the wound.
Study: NCT05812807

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation
Description: Undergo observation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05250908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTIBIA Therapeutic
Description: INTIBIA implantable tibial nerve stimulator with therapeutic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTIBIA Non-Therapeutic
Description: INTIBIA implantable tibial nerve stimulator with non-therapeutic stimulation for 3 months, then therapeutic stimulation
Study: NCT06300411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRG-514
Description: SRG-514 monotherapy
Study: NCT06288438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Techniques
Description: Motivational Interviewing Techniques including but not limited to open-ended questions, reflection, affirmations, and summary will be used to build participant rapport, support behavior change (physical activity), and facilitate program engagement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Interventions
Description: Strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise.

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Education on general health topics which may include the following: basic nutrition, stress reduction, sleep hygiene, etc.

Intervention type: OTHER
Group type: OTHER
Intervention: Health Status Updates
Description: Health Status Updates will be completed by a trained assessor. The assessor will ask about adverse events, general health topics, medication changes, and changes in social circumstances.

Intervention type: OTHER
Group type: OTHER
Intervention: Physical Therapy Consult
Description: Participants in the control condition will be offered a physical therapy consult at the end of their 24 week study involvement.
Study: NCT06634875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isunakinra
Description: Isunakinra is a potent IL1R1 inhibitor
Study: NCT05629286

Intervention type: DEVICE
Intervention: McConnell taping
Description: non-stretch rigid McConnell tape will be applied

Intervention type: DEVICE
Intervention: McConnell taping
Description: non-stretch rigid McConnell tape will be applied

Intervention type: DEVICE
Intervention: Patella Stabilizer Brace
Description: An orthotic application that wraps the patellofemoral joint, which has a patellar cavity and supports the patella, and provides stabilization with velcro

Intervention type: DEVICE
Intervention: Patella Stabilizer Brace
Description: An orthotic application that wraps the patellofemoral joint, which has a patellar cavity and supports the patella, and provides stabilization with velcro
Study: NCT06632080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Substance P
Description: The participants will receive a continuous intravenous infusion of 20 mL of substance P (1.5 pmol/kg/min) over 20 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will receive a continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.
Study: NCT05761366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Al18F-PSMA-BCH PET/CT
Description: Patients will be intravenously injected with Al18F-PSMA-BCH and undergo PET/CT scan.
Study: NCT05617326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AAA screening by a GP
Description: The GPs included in the experimental group will be trained in AAA screening with an ultra-portable ultrasound machine and will keep an ultrasound machine available (Butterfly iQ+ model). Their patients will be able to be screened by the GP in the office or at home. In case of positive screening, the GP will be able to refer the patients to the radiologist for diagnostic confirmation..

Intervention type: OTHER
Group type: OTHER
Intervention: AAA screening by a radiologist
Description: General practitioners in the control group will refer their patients to the radiologist for AAA screening.
Study: NCT06016842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor
Description: Duration: up to an estimated 42-month (3.5-year) double-blind treatment period during which elafibranor 80 mg tablet will be administered once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched 80 mg placebo
Description: Duration: up to an estimated 42-month (3.5-year) double-blind treatment period during which matching placebo tablet will be administered once daily
Study: NCT06256055

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMYM802 Injection
Description: 1×10\^8\~2×10\^9 cells will be infused intravenously for 4 times.
Study: NCT05467410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COG-AM
Description: Participants who are randomized to the COG-AM intervention group will be asked to complete 30-minute computerized cognitive training (Lumosity cognitive training program) sessions during morning hours (between 09:00-12:00), for a total of 7 days or until hospital discharge, whichever comes first. Participants will complete cognitive training sessions in each of the following subdomains: memory, attention, problem solving, cognitive flexibility, and processing speed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COG-PM
Description: Participants who are randomized to the COG-PM intervention group will be asked to complete 30-minute computerized cognitive training (Lumosity cognitive training program) sessions during late afternoon/early evening hours (between 15:00-18:00), for a total of 7 days or until hospital discharge, whichever comes first. Participants will complete cognitive training sessions in each of the following subdomains: memory, attention, problem solving, cognitive flexibility, and processing speed.
Study: NCT05534867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandala coloring
Description: Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 16 mandala coloring pages given to each participant by the researcher for 1 month, 2 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
Study: NCT06564857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Age \< 70 years: Bolus of 4 μg/kg Ideal Body Weight remifentanil at anaesthesia induction; Age \>= 70 years: Bolus of 2 μg/kg ideal Body Weight remifentanil at anaesthesia induction
Study: NCT06490887

Intervention type: OTHER
Intervention: Use of patient-derived biological samples
Description: We will use biological samples that are routinely collected as waste material from patients undergoing surgery or from pregnant women giving birth. Peripheral blood will be also collected from patients to conduct virological screening and isolate peripheral blood mononuclear cells.

Intervention type: OTHER
Intervention: Use of patient-derived biological samples
Description: We will use biological samples that are routinely collected as waste material from patients undergoing surgery or from pregnant women giving birth. Peripheral blood will be also collected from patients to conduct virological screening and isolate peripheral blood mononuclear cells.

Intervention type: OTHER
Intervention: Use of patient-derived biological samples
Description: We will use biological samples that are routinely collected as waste material from patients undergoing surgery or from pregnant women giving birth. Peripheral blood will be also collected from patients to conduct virological screening and isolate peripheral blood mononuclear cells.
Study: NCT06564857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Bolus of 0.6 mg/kg Ideal Body Weight rocuronium at anaesthesia induction
Study: NCT06399224

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Local Plantar vibrator
Description: A vibrating device that applies 80 hz vibration waves applied on the sole of the foot

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Otago exercise
Description: Warm up Front Knee strength Back knee strength Side hip strength Calf raising Toe raising Sit to stand Heel walk Toe walk One leg standing Side way walk Cool down

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Otago exercise
Description: Warm up Front Knee strength Back knee strength Side hip strength Calf raising Toe raising Sit to stand Heel walk Toe walk One leg standing Side way walk Cool down
Study: NCT05424302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Vestibular Rehabilitation with Adjunct At Home Virtual Reality Vestibular Rehabilitation
Description: The virtual reality intervention will involve standard vestibular rehabilitation as described above and adjunct at home virtual reality video game. This video game will be projected on an android or apple device accommodated into a VR headset for 20 minutes daily until the vestibular rehabilitation is complete. This video will be congruent to current vestibular rehabilitation program exercises. Point-of-view games compatible with both Android and iOS devices will be evaluated by professionals to determine the game that is most representative of current evidence based exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Vestibular Rehabilitation with Adjunct Auditory Intervention
Description: The control intervention will involve standard vestibular rehabilitation as described above and adjunct audio intervention while wearing the VR headset for 20 minutes daily until the vestibular rehabilitation is complete.
Study: NCT05817318

Intervention type: DEVICE
Group type: OTHER
Intervention: Renal Denervation
Description: Arrhythmia burden pre-to-post renal denervation as assessed by an implantable cardiac monitor
Study: NCT05692947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Core body temperature device
Description: This study is to verify the claims of CORE™ body temperature system to estimate core body temperature from skin temperature and heart rate during exercise under varying environmental conditions. Subjects will ingest a temperature sensing pill and be outfitted with skin temperature sensors, a chest strap heart rate monitor, and the CORE and CaleraResearch devices. Athletes will run or cycle in hot/dry and hot/humid conditions for 45 minutes at an absolute workload of 60% VO2 Max/Peak.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Core body temperature device
Description: This study is to verify the claims of CORE™ body temperature system to estimate core body temperature from skin temperature and heart rate during exercise under varying environmental conditions. Subjects will ingest a temperature sensing pill and be outfitted with skin temperature sensors, a chest strap heart rate monitor, and the CORE and CaleraResearch devices. Athletes will run or cycle in hot/dry and hot/humid conditions for 45 minutes at an absolute workload of 60% VO2 Max/Peak.
Study: NCT04643405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1387 for Injection
Description: APG1387 will be administered IV days 1， 8, 15 and 22 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-Paclitaxel 125mg/m\^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
Study: NCT05505279

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THRIVE (High Flow Nasal Cannula)
Description: 2 different rates of nasal flow compared to each other and a baseline of level of nasal oxygen

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THRIVE (High Flow Nasal Cannula)
Description: 2 different rates of nasal flow compared to each other and a baseline of level of nasal oxygen